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A B S T R A C T
Dogs are the main domestic reservoir of Leishmania infantum, and in cases of uncontrolled infection, a strong
humoral immune response is elicited, which is inefficient against the parasites. Previous studies have suggested
that an adequate antigen/antibody ratio, with a moderate prevalence of antigens with respect to the antibodies,
could result in the formation of circulating immune complexes (CIC) in canine leishmaniosis (CanL). Deposition
of these complexes in tissues has been associated with vasculitis, uveitis, arthritis, dermatitis and especially
glomerulonephritis and renal failure. However, little is known about the relationship between the presence of
CIC and disease progression. The aim of this study was to evaluate serum CIC level and its correlation with
disease severity in infected dogs with different stages of disease and non-infected animals as a control. A total of
60 dogs were included in the study, classified according to the proposed LeishVet classification criteria: healthy
non-infected (n= 13); healthy infected (n= 12); sick stage I (n=9); sick stage II (n=17); sick stage III
(n=8); and sick stage IV (n=1). CIC were isolated from serum samples using a modified polyethylene glycol
precipitation method, and their levels measured by ELISA and bicinchoninic acid protein assay. A nanoparticle
tracking analysis was performed to investigate the relationship between the molecular size distribution of the
CIC and disease progression. In conclusion, the results confirmed a positive association between CIC levels, their
molecular size and disease progression that suggests a potential use of CIC as biomarkers of CanL.
1. Introduction
Canine leishmaniosis (CanL) is a global zoonotic disease caused by
the parasite Leishmania infantum and transmitted by phlebotomine sand
flies; the main arthropod vector is Phlebotomus perniciosus (Willen et al.,
2018). CanL is endemic in the Mediterranean Basin, Central and South
America and some regions of Asia. It is recognized as a major problem
for both veterinary medicine and public health, given that dogs are the
main domestic reservoir of L. infantum (Dantas-Torres, 2007; Galvez
et al., 2010).
Macrophages infected with Leishmania parasites are ruptured due to
hypertrophic growth leading to the release of the amastigote forms.
These amastigotes trigger the humoral immune response, and in ani-
mals unable to limit the infection, this leads to a large and uncontrolled
antibody production which is inefficient against parasites (Jamal et al.,
2017). Persistent infection associated with prolonged presence of
parasite antigens can result in the formation of circulating immune
complexes (CIC) (Nydegger, 2007), formed mainly by IgG, IgM and
complement system components in addition to antigens from the
parasite (Poli et al., 1991). Defective clearance of these CIC by
scavenging macrophages leads to their deposition in specific organs.
Several studies in animal models and also in humans have at-
tempted to elucidate the role of CIC in the pathology of visceral leish-
maniosis (VL) (Requena et al., 2000; Miles et al., 2005; Elshafie et al.,
2007), suggesting that disease complications may be partly accounted
by CIC deposition-related pathology, particularly nephritis (Poli et al.,
1991; Lopez et al., 1996; Costa et al., 2003; Plevraki et al., 2006). CIC-
related renal pathology plays a pivotal role in prognosis, and it has been
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adopted as a major criterion for clinical staging of the disease in dogs
(Paltrinieri et al., 2010; Solano-Gallego et al., 2011; Roura et al., 2013).
Immune complexes have been detected in the sera of Leishmania-in-
fected dogs, and the pathogenesis of renal lesions has been mainly at-
tributed to CIC deposition and subsequent glomerular injury (Tafuri
et al., 1989; Poli et al., 1991; Nieto et al., 1992; Margarito et al., 1998;
Solano-Gallego et al., 2003).
Several assay systems have been developed for detection of soluble
complexes (Sobel et al., 1975; Hay et al., 1976; Digeon et al., 1977;
Levinsky and Soothill, 1977), with different success rates. Previous
studies have highlighted the importance of CIC in the pathogenesis of a
variety of systemic disorders such as autoimmune diseases (Abrass
et al., 1980; Nydegger and Davis, 1980; Bernstein et al., 1994), allergic
diseases (Paganelli et al., 1981; Park and Nahm, 1998) and infectious
diseases (Miles et al., 1993; Sengupta et al., 2002; Koraka et al., 2003).
This suggests that CIC may be considered potential biomarkers of dis-
ease activity due to their diagnostic and prognostic value (Urbaniak-
Kujda, 1996; Brunner and Sigal, 2001; Jaiswal et al., 2018;
Thanadetsuntorn et al., 2018). In this sense, quantification of CIC in
cases of CanL could be an alternative disease biomarker not only for
diagnosis but also for tracking disease progression and potentially for
monitoring the success of treatment in dogs.
Thus, the aim of this study was to determine the presence of CIC in
naturally infected dogs suffering from clinical CanL at different stages
and to investigate the correlation between CIC levels and disease pro-
gression.
2. Materials and methods
2.1. Experimental population
The experimental population consisted of 60 dogs brought by their
owners to the hospital clinic (Veterinary Teaching Hospital,
Universidad Complutense de Madrid, Spain) and breeder and hunting
dogs at their respective kennels undergoing a CanL check-up over the
period December 2013 to June 2014. The owners of the selected dogs
were informed beforehand about the study protocol and gave their
informed consent.
Animals were classified into the following leishmaniosis clinical
stages according to the LeishVet classification (Solano-Gallego et al.,
2009, 2011) based on clinical signs, clinical-pathologic abnormalities
and serologic status: healthy non-infected (H, n=13); healthy infected
(HI, n= 12); sick stage I (SS1, n= 9); sick stage II (SS2, n= 17); sick
stage III (SS3, n= 8); and sick stage IV (SS4, n= 1).
Selection criteria included male or female dogs, not previously
vaccinated against L. infantum or treated in the previous two months
with any leishmanicidal/leishmanistatic drugs. Dogs infected with
other vector-borne pathogens (i.e. Ehrlichia spp., Babesia spp. or
Dirofilaria spp.) were excluded to avoid misinterpretation of clinical
signs and/or clinical-pathologic abnormalities.
2.2. Serum sample collection
Approximately 8mL of whole blood from each dog were collected
and kept at room temperature for approximately 30min and then
centrifuged at 1000× g for 10min at 4 °C. After centrifugation, a
minimum volume of 4mL of serum per animal was obtained and stored
at −20 °C until use.
2.3. CIC isolation
Serum samples were processed for CIC isolation using a modifica-
tion of a previously reported method (Raja et al., 1995). Briefly, sam-
ples were centrifuged and the upper layer collected and mixed with an
equal volume of 7% polyethylene glycol (PEG; Sigma-Aldrich, St Louis,
MO, USA) and kept overnight. Afterwards, PEG-precipitated CIC were
pelleted by centrifugation and then reconstituted in 0.01M phosphate
buffered saline (PBS) and stored at −80 °C for further use. CIC protein
content was estimated by using a bicinchoninic acid (BCA) protein
assay kit (Thermo Fisher Scientific, Waltham, MA, USA).
2.4. L. infantum culture and soluble antigen preparation
L. infantum (MCAN/ES/1996/BCN/150/MON-1) parasites were
grown at 26 °C in Schneider's medium (Sigma-Aldrich) supplemented
with 20% heat-inactivated fetal bovine serum (Sigma-Aldrich), 20mM
L-glutamine, 200 U/mL penicillin and 100 μg/mL streptomycin at pH
7.4 (Fernandez-Cotrina et al., 2013).
Soluble Leishmania antigen (SLA) was prepared from stationary-
phase promastigotes of L. infantum, as reported previously (Iborra et al.,
2004). Briefly, 2×108 promastigotes were washed three times in cold
sterile PBS and subjected to six cycles of freezing and thawing. After
five cycles (30 s at 38MHz) of ultrasonication (Labsonic®M, Sartorious,
Goettingen, Germany), the suspension was centrifuged at 8000 xg for
30min at 4 °C and the supernatant containing the SLA was collected.
Protein concentration was estimated by the Bradford method (Bio-Rad,
Hercules, CA USA), and 500 μL aliquots were stored at −80 °C.
2.5. Levels of CIC
An enzyme-linked immunosorbent assay (ELISA) procedure was
used to measure PEG-precipitated CIC. Briefly, microtiter immunoassay
plates (NUNC, Roskilde, Denmark) were coated with SLA (10 μg/mL in
0.01M PBS) overnight at 4 °C. Microplates were washed four times with
PBS containing 0.1% Tween 20 (PBS-T) and blocked with 200 μL/well
of PBS-T supplemented with 1% BSA (Sigma-Aldrich) at room tem-
perature (RT). After washing, microplates were incubated with a 1:100
dilution of precipitated CIC for 1 h at RT. Microplates were then washed
and incubated with HRP-conjugated anti-dog IgG (Bethyl Laboratories,
Montgomery, TX USA) (1:10,000) at RT for 1 h. After washing, micro-
plates were developed with a solution of Sigma Fast o-phenylene dia-
mine dihydrochloride (OPD) and H2O2 in phosphate-citrate buffer.
After 30min, the reaction was stopped by adding a solution of 2 N
H2SO4, and microplates read at 450 nm in an ELISA microplate spec-
trophotometer (Bio-Rad).
All samples were tested in duplicate and the mean value was re-
corded. Mean OD+2 Standard Deviation of the control group (group
H) was considered as the cutoff value; any sample exhibiting absor-
bance above the cutoff value was considered positive.
2.6. Determination of leishmania-specific antibodies in serum samples by
immunofluorescence antibody testing (IFAT)
Specific IgG antibodies against in-house cultured promastigotes
were evaluated as reported elsewhere (Mancianti and Meciani, 1988),
using serial dilutions from 1:50 to 1:12,800; seropositivity was defined
by a cut-off ≥ 1:100.
2.7. Analysis of particle distribution
Absolute particle distribution (size and concentration) was analyzed
by nanoparticle tracking analysis (NTA) using a NanoSight NS300
(Malvern Panalytical, Malvern, UK) equipped with a sample chamber
and 405 nm laser.
PEG-precipitated CIC were injected into the sample chamber with
sterile syringes until the liquid reached the tip of the nozzle. NTA
measurement conditions were: temperature= 22 °C;
viscosity= 0.95 cP; frames per second= 21; measurement time=91 s;
three recordings performed per sample.
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2.8. Statistical analysis
Data from groups SS3 and SS4 were merged and analyzed together
due to the relatively low number of animals classified in the group SS4
included in the study.
Nonparametric Student’s t-tests (Mann-Whitney) were performed
with GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA,
USA). Data were expressed as mean ± standard error mean (SEM), and
differences were considered statistically significant when p < 0.05.
Correlation coefficient (r value) and statistical significance of pair-
wise comparisons between PEG-precipitated CIC levels and IFAT titer or
total protein content were determined using Spearman’s correlation.
3. Results
3.1. Measurement of PEG-precipitated CIC
PEG-precipitated CIC levels are shown in Fig. 1. No CIC were de-
tected either in group H (healthy non-infected animals) or in group HI
(healthy infected animals).
Statistically significant differences were observed between groups
SS2 (p < 0.01) and SS3/SS4 (p < 0.001) compared to group H. No
statistically significant differences (p=0.052) were detected between
group SS1 and the control group (H).
3.2. Protein content in PEG-precipitated CIC
PEG-precipitated CIC protein content is shown in Fig. 2A. Protein
content was significantly higher (p < 0.05) in sick groups (SS1, SS2
and SS3/SS4) compared to the control group (H).
A significant positive correlation was obtained between protein
concentration and levels of PEG-precipitated CIC (r= 0.747;
p < 0.001) (Fig. 2B).
3.3. IFAT analysis
Leishmania-specific IgG determined by IFAT ranged from negative
(no reactivity) to 1:6400. Statistically significant differences in IgG ti-
ters were observed between groups SS1 (p < 0.05), SS2 and SS3/SS4
(p < 0.001) compared to group H. Dogs in groups SS2 and SS3/SS4
showed the highest antibody titers (Fig. 3A).
Fig. 3B shows a statistically significant positive correlation between
IFAT titers and levels of PEG-precipitated CIC (r= 0.754; p < 0.001).
3.4. Particle distribution
The analysis of absolute particle distribution (size and concentra-
tion) in PEG-precipitated serum samples is shown in Fig. 4.
Large amounts of small, non-aggregated particles (70 nm) were
observed in groups H, HI and SS1. In contrast, groups SS2 and SS3/SS4
showed a size distribution ranging from 100 to 400 nm, associated with
larger protein aggregates, mainly detected at 100, 190, 280, and
400 nm.
4. Discussion
The source of CIC as a consequence of Leishmania infection has been
associated with formation of huge aggregates of parasite proteins, anti-
Leishmania IgG and IgM and to a lesser extent complement components
(Mancianti et al., 1989; Lucena et al., 1994). In this sense, their de-
position in specific organs has been determined to be one of the main
causes responsible for tissue damage, related to renal failure and
eventually death in CanL (Costa et al., 2003; Ordeix et al., 2005). Al-
though different published studies have suggested that the concentra-
tion of CIC is related to disease progression (Margarito et al., 1998;
Miles et al., 2005), there have been no studies directly correlating
clinical signs in CanL with CIC concentration.
To this purpose we developed a method to isolate CIC and quantify
their levels in serum samples obtained from dogs naturally infected
with L. infantum. Although the method exclusively provides levels of
PEG-precipitated CIC based on a colorimetric assay and expressed in
optical densities, it provided a useful tool for measuring the con-
centration in serum samples, enabling comparison between different
groups. This study shows the importance of implementing a robust,
fully validated method to quantify them.
This preliminary approach to measure the CIC levels enabled us to
establish a statistically significant correlation between immune com-
plexes and pathology stage in animals infected with L. infantum. As
expected, healthy non-infected and healthy infected animals did not
show CIC, while there was a direct relationship of CIC levels and disease
progression in the sick dogs, in accordance with results demonstrated
for other pathologies (Tuzun et al., 2004; Sheerin et al., 2006). The
presence of CIC has been associated with complications in severely ill
individuals suffering from different infectious diseases (Goedvolk et al.,
2003; Monsalvo et al., 2011; Thomas et al., 2012).
IFAT is one of the most commonly used serologic methods to di-
agnose leishmaniosis, considered the “gold standard” test for
Leishmania infection (Maia and Campino, 2008; Reis et al., 2009). Its
correlation with clinical signs and the deposition of CIC has been in-
vestigated in-depth (Zatelli et al., 2003; Aresu et al., 2013; dos Santos
et al., 2013; Rigo et al., 2013; Koutinas and Koutinas, 2014). In this
sense, it is widely known that dogs with the highest level of antibodies
tend to have the worst clinical manifestations, although some excep-
tions are not infrequent, as other authors have reported (Dantas-Torres
et al., 2006; Miró et al., 2007). In our study, we saw a positive corre-
lation between IFAT titers and CIC levels of animals in groups SS2 and
SS3/SS4, as confirmed by statistical analyses (p < 0.001).
Another important issue in determining pathogenicity of CIC could
be related to their molecular size, as suggested in previous studies in
human immune complex diseases and animal models (Cochrane and
Hawkins, 1968; Levinsky et al., 1977; Tung et al., 1981; Mageed et al.,
1991; Korolevskaya et al., 2014). In addition to their conformation and
charge, the deposition site of the immune complexes is related to their
size, which has been shown to play a relevant role in the glomerular
pattern of injury in Leishmania infected dogs (Marcussen et al., 1989;
Poli et al., 1991; Nieto et al., 1992; Costa et al., 2003; Zatelli et al.,
Fig. 1. Levels of polyethylene glycol (PEG)-precipitated circulating immune
complexes (CIC).
CIC quantification was performed in PEG-precipitated serum samples from
different groups (healthy non-infected (H); healthy infected (HI); sick stage I
(SS1); sick stage II (SS2); sick stage III / sick stage IV (SS3/SS4)). Data show
values of individual animals and mean ± SEM. Low levels of CIC were detected
in groups H and HI while statistically significant differences, determined using
nonparametric Student´s t-test (Mann-Whitney), were observed between groups
SS2 and SS3/SS4 in comparison to healthy controls (**p < 0.01;
***p < 0.001).
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2003). As far as we know, there have been no previous studies reporting
CIC size in CanL or correlating their size and disease severity. Thus, we
applied NTA technology, a powerful technique that is particularly va-
luable for analyzing protein aggregates, to study CIC size in PEG-pre-
cipitated serum samples (Filipe et al., 2010). The data revealed that
dogs with more severe clinical signs (groups SS2 and SS3/SS4)
presented larger-sized protein aggregates, whereas a higher quantity of
smaller-sized aggregates was observed in dogs included in groups H, HI
and SS1. These results demonstrate a clear positive correlation between
the clinical stage of the disease and the size of precipitated CIC pro-
viding additional evidence about their pathogenic role, as has been
suggested in previous published studies (Mannik, 1980; Nangaku and
Fig. 2. Polyethylene glycol (PEG)-precipitated
circulating immune complexes (CIC) protein
content (A) and correlation with the levels of
PEG-precipitated CIC (B).
A. CIC protein content in PEG-precipitated
serum samples from different groups (healthy
non-infected (H); healthy infected (HI); sick
stage I (SS1); sick stage II (SS2); sick stage III /
sick stage IV (SS3/SS4)), determined by BCA
protein assay kit. Data show individual values
and mean ± SEM. Statistical significance de-
termined using nonparametric Student´s t-test
(Mann-Whitney) in comparison to healthy
controls for each group is indicated
(*p < 0.05).
B. Correlation between protein concentration
(μg/μl) and levels (O.D. 450 nm) of PEG-pre-
cipitated CIC. Spearman´s correlation
(r= 0.747, p < 0.001).
Fig. 3. Immunofluorescence Antibody Testing
(IFAT) analysis (A) and correlation between
IFAT and polyethylene glycol (PEG)-pre-
cipitated circulating immune complexes (CIC)
levels (B).
A. Reciprocal IFAT titers/animal of different
groups (healthy non-infected (H); healthy in-
fected (HI); sick stage I (SS1); sick stage II
(SS2); sick stage III / sick stage IV (SS3/SS4))
and mean ± SEM values. Comparison be-
tween groups was determined by nonpara-
metric Student´s t-test (Mann-Whitney) in
comparison to healthy controls for each group.
Statistical significance is indicated (*p < 0.05;
***p < 0.001).
B. Correlation between IFAT titer and levels
(O.D. 450 nm) of PEG-precipitated CIC.
Spearman´s correlation (r= 0.754;
p < 0.001).
Fig. 4. Particle distribution (size and con-
centration) in polyethylene glycol-precipitated
serum samples from the five groups of animals.
The analysis of particle distribution was eval-
uated by Malvern Panalytical NanoSight
NS300 technology. The chromatogram con-
firms that samples of groups: sick stage II (SS2)
and sick stage III / sick stage IV (SS3/SS4),
contain larger protein aggregates and an in-
crease in the concentration of precipitated
particles (high size, expressed in nm), in con-
trast with higher concentrations of small par-
ticles (low size, expressed in nm) observed in
healthy non-infected (H); healthy infected (HI)
and sick stage I (SS1) groups.
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Couser, 2005; Korolevskaya et al., 2014).
Accurate assessment of CanL disease severity is necessary to support
veterinarians, not only to confirm Leishmania infection but also to
follow-up on the response to treatment. This would enable selection of
appropriate therapeutic approaches and give a realistic prognosis to
apparently healthy and sick dogs (Solano-Gallego et al., 2017; Maia and
Campino, 2018). Despite the recent advances made in biomarkers re-
lated to Leishmania pathogenesis in different organs and tissues, due to
invasive sampling and limited access to tools for evaluation of biolo-
gical markers, most cannot be used in a laboratory setting (Maia and
Campino, 2008). Nonetheless, and taking into account the above re-
sults, a non-invasive method to evaluate CIC levels (i.e. characterization
of serum samples) would be a valuable tool to not only diagnose but
also predict disease progression and potentially monitor the success of
treatment in dogs. Furthermore, measurement of CIC as a biomarker for
disease progression may provide interesting information regarding the
ability of vaccines or immunotherapy treatments to control the disease.
Undoubtedly, although other aspects about the origin and composition
of CIC remain unknown, their relationship with disease progression has
been definitively established.
5. Conclusion
This study reports a method to estimate CIC levels in dogs infected
with Leishmania and demonstrates a direct correlation between those
levels and the disease stage. Nevertheless, more studies are required to
not only improve detection of CIC, but to further characterize them. To
better understand the specific role of immune complexes in CanL and
disease progression, it is crucial to determine the diagnostic, prognostic,
and pathogenic importance of CIC. Thus, the future for the use of CIC as
a biomarker for monitoring disease progression in CanL is promising.
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